Lupin's Bold Move: Rs 1970 Crore Visufarma Acquisition Set to Reshape Ophthalmic Market
Lupin's Latest Triumph: US FDA Greenlight for HIV Drug Ignites Stock Rally
Decoding the Paradox: Why Indian Pharma Stocks Are Plummeting Even After US Tariff Relief